

Table of contents

Contents	Page No.
<i>Certificate</i>	<i>i</i>
<i>Acknowledgements</i>	<i>ii</i>
<i>Abstract</i>	<i>x</i>
<i>List of Tables</i>	<i>xii</i>
<i>List of Figures</i>	<i>xiii</i>
<i>Abbreviations</i>	<i>xiv</i>
Chapter I: Introduction	1-53
1. Tuberculosis	1-4
1.1. <i>Mycobacterium tuberculosis</i> - the etiological agent of TB	5
1.2. <i>Mycobacterium tuberculosis</i> (MTB): An overview	5-6
1.3. Classification of mycobacteria	6-8
1.4. The <i>Mycobacterium tuberculosis</i> genome	8
1.5. The mycobacterial cell envelope	8-12
1.6. Tuberculosis: Drug resistance	12-13
1.6.1. Multidrug-resistant TB (MDR TB)	13-14
1.6.2. Extensively Drug-Resistant TB (XDR TB)	14
1.6.3. Totally drug-resistant TB (TDR TB) or extremely drug resistant TB (XXDR TB)	14-15
1.6.4. Rifampicin-resistant TB (R TB)	15
1.7. TB in HIV	15-16
1.8. Current treatment in TB	17
1.8.1. Treatment for latent-TB infection (LTBI)	17
1.8.2. Treatment for drug susceptible-TB	17-18
1.8.3. Treatment for drug resistant-TB	18-19

Contents	Page No.
1.9. Classification of anti-TB drugs	20
1.9.1. Cell wall synthesis inhibitors	20-22
1.9.2. Nucleic Acid Synthesis Inhibitors	22-24
1.9.3. Protein synthesis Inhibitors	24-25
1.9.4. Electron transport across membrane inhibitors	25-26
1.10. Current emerging pipeline new anti-TB drugs	27-28
1.10.1. Q203	28-29
1.10.2. Sutezolid	29
1.10.3. SQ109	30-31
1.10.4. Levofloxacin (LEV)	31-32
1.10.5. Delamanid	32-33
1.10.6. Pretomanid (PA-824)	33-34
1.10.7. Rifapentine	34
1.10.8. Moxifloxacin	34-35
1.10.9. Bedaquiline	35-37
1.11. Molecular Modification	37-38
1.11.1. Prodrug approach	38-39
1.11.2. Bioisosterism	39-43
1.11.3. Molecular hybridization (MH)	43-45
1.12. References	45-53
Chapter II: Objectives	54
Chapter III: Identification and development of 1-((1-(substituted)-1<i>H</i>-1,2,3-triazol-4-pyrazolo[4,3-<i>c</i>]pyridine-5(4<i>H</i>)-carboxamides as <i>Mycobacterium tuberculosis</i> Pantothenate synthetase inhibitors	55-87
3.1. Introduction	55-58
3.1.1. Design and chemistry	58-59
3.2. Results and Discussion	59-60

Contents	Page No.
3.2.1. <i>In vitro</i> MTB screening	60-62
3.2.2. Pantothenate synthetase enzyme inhibition studies	63-64
3.2.3. Docking study	64-65
3.2.4. <i>In vitro</i> cytotoxicity studies	66
3.2.5. Single Crystal X-ray Crystallographic Structure of Compound 7g	66-68
3.3. Conclusion	69
3.4. Experimental	69
3.4.1. Materials and methods	69
3.4.2. Chemistry	69-83
3.4.3. Biological activity	83
3.4.3.1. MTB PS screening	83
3.4.3.2. <i>In vitro</i> MTB screening	83-84
3.4.3.3. <i>In vitro</i> cytotoxicity screening	84
3.4.4. Docking Study	84-85
3.5. References	85-87
Chapter IV: Design, synthesis of 9H-fluorenone based 1,2,3-triazole analogues as <i>Mycobacterium tuberculosis</i> InhA inhibitors	88-138
4.1. Introduction	88-93
4.2. Results and Discussion	93
4.2.1. Chemistry	93-95
4.2.2. <i>In vitro</i> MTB screening	95-99
4.2.3. InhA enzyme Inhibition studies	99-100
4.2.4. Docking study	100-104
4.2.5. <i>In vitro</i> cytotoxicity studies	104
4.2.6. Single Crystal X-ray Crystallographic Structure of Compound 15a	105-106
4.2.6.1. Single Crystal X-ray Crystallographic Structure of Compound 15r	107-108
4.3. Conclusion	109

Contents	Page No.
4.4. Experimental section	109
4.4.1. Materials and methods	109
4.4.2. Chemistry	110-128
4.4.3. Biological activity	128
4.4.3.1. InhA activity inhibition	128
4.4.3.2. <i>In vitro</i> MTB screening	129
4.4.3.3. <i>In vitro</i> cytotoxicity screening	129
4.4.4. Docking Study	130
4.5. References	130-133
Chapter V: Design, synthesis and biological evaluation of new substituted sulfonamide tetrazole derivatives as anti-tubercular agents	134-165
5.1. Introduction	134-138
5.2. Results and Discussion	138
5.2.1. Chemistry	138-140
5.2.2. Antimycobacterial activity	140-144
5.2.3. Cytotoxicity assay	144-145
5.3. Conclusion	146-145
5.4. Experimental section	146
5.4.1. Materials and methods	146
5.4.2. Chemistry	146-162
5.4.3. Anti-tubercular activity against MTB H ₃₇ R _v strain	162-163
5.4.4. CHO-K1 Cytotoxicity	163
5.5. References	163-165
Chapter VI: 6-chloro, 6,7-dichloro and 2-methyl-3-(((1-(substitutedphenyl)-1H-1,2,3-triazol-4-yl)methoxy)carbonyl)quinoxaline 1,4-dioxide derivatives as anti-tubercular agents	166-191
6.1. Introduction	166-169

Contents	Page No.
6.2. Results and Discussion	169
6.2.1. Chemistry	169-170
6.2.2. <i>In vitro</i> MTB screening	170-174
6.2.3. <i>In vitro</i> cytotoxicity studies	174
6.3. Conclusion	175
6.4. Experimental	175
6.4.1. Materials and methods	170
6.4.2. Chemistry	176-188
6.4.3. Biology	188
6.4.3.1. <i>In vitro</i> MTB screening	188
6.4.3.2. <i>In vitro</i> cytotoxicity screening	188-189
6.5. References	189-191
Chapter IX: Summary and Conclusion	192-194
Future perspectives	195
Appendix	196-198
List of publications	196-198
List of papers presented at conferences	198
Biography of supervisor	199
Biography of candidate	199



This document was created with the Win2PDF "print to PDF" printer available at <http://www.win2pdf.com>

This version of Win2PDF 10 is for evaluation and non-commercial use only.

This page will not be added after purchasing Win2PDF.

<http://www.win2pdf.com/purchase/>